JP4880854B2 - 高い免疫反応性を有するタンパク質及びその製造方法 - Google Patents

高い免疫反応性を有するタンパク質及びその製造方法 Download PDF

Info

Publication number
JP4880854B2
JP4880854B2 JP2001575649A JP2001575649A JP4880854B2 JP 4880854 B2 JP4880854 B2 JP 4880854B2 JP 2001575649 A JP2001575649 A JP 2001575649A JP 2001575649 A JP2001575649 A JP 2001575649A JP 4880854 B2 JP4880854 B2 JP 4880854B2
Authority
JP
Japan
Prior art keywords
protein
mak
immunoreactive
molecules
immunoreactivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001575649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530126A (ja
JP2003530126A5 (enExample
Inventor
エフ ベーネス イヴァン
トムセン−ボスレート ジルケ
Original Assignee
シンテック ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンテック ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical シンテック ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2003530126A publication Critical patent/JP2003530126A/ja
Publication of JP2003530126A5 publication Critical patent/JP2003530126A5/ja
Application granted granted Critical
Publication of JP4880854B2 publication Critical patent/JP4880854B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001575649A 2000-04-05 2001-04-04 高い免疫反応性を有するタンパク質及びその製造方法 Expired - Fee Related JP4880854B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10016877A DE10016877A1 (de) 2000-04-05 2000-04-05 (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung
DE10016877.9 2000-04-05
PCT/EP2001/003867 WO2001077179A1 (de) 2000-04-05 2001-04-04 Proteine mit hoher immunreaktivität sowie ein verfahren zu ihrer herstellung

Publications (3)

Publication Number Publication Date
JP2003530126A JP2003530126A (ja) 2003-10-14
JP2003530126A5 JP2003530126A5 (enExample) 2008-04-03
JP4880854B2 true JP4880854B2 (ja) 2012-02-22

Family

ID=7637638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001575649A Expired - Fee Related JP4880854B2 (ja) 2000-04-05 2001-04-04 高い免疫反応性を有するタンパク質及びその製造方法

Country Status (10)

Country Link
US (3) US7264805B2 (enExample)
EP (1) EP1276770B1 (enExample)
JP (1) JP4880854B2 (enExample)
AT (1) ATE376000T1 (enExample)
CY (1) CY1107136T1 (enExample)
DE (2) DE10016877A1 (enExample)
DK (1) DK1276770T3 (enExample)
ES (1) ES2295160T3 (enExample)
PT (1) PT1276770E (enExample)
WO (1) WO2001077179A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10016877A1 (de) * 2000-04-05 2001-10-18 Scintec Diagnostics Gmbh Zug (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung
RU2016134843A (ru) 2009-04-30 2018-12-11 Тел Хашомер Медикал Рисерч Инфрастракче Энд Сервисиз Лтд. Антитела к ceacam1 и способы их использования
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
KR102452349B1 (ko) 2014-04-27 2022-10-11 페임웨이브 리미티드 Ceacam1에 대한 인간화 항체
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5452986A (en) * 1985-02-28 1986-09-24 Verax Corp. Fluidized bioreactor and cell cultivation process
US5164175A (en) * 1986-12-10 1992-11-17 Hoechst Aktiengesellschaft Diagnostic aid containing an organ-specific substance labeled with technetium-99m
US4939087A (en) * 1987-05-12 1990-07-03 Washington State University Research Foundation, Inc. Method for continuous centrifugal bioprocessing
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
DE4125625C2 (de) * 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
AU667530B2 (en) * 1992-05-28 1996-03-28 New York Blood Center, Inc., The Removal of antibodies from blood-derived compositions while retaining coagulation factors
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
SE9500148D0 (sv) 1995-01-18 1995-01-18 Bioinvent Internatioal Ab Antibodies for use in cancer therapy and diagnosis
EP0727480A3 (de) 1995-02-16 2000-04-12 Forschungszentrum Jülich Gmbh Verfahren zur Bestimmung von Pharmakokinetik bzw. Toxikokinetik von Testsubstanzen mit Hilfe von in-vitro-Zellkultursystemen und dafür geeignete Vorrichtungen
DE19521388C2 (de) 1995-06-13 1997-05-22 Immuno Gmbh Technik zur Bestimmung einer spezifisch-bindefähigen Substanz
DE19621388A1 (de) 1996-05-28 1997-12-11 Torsten Urban Das Tapeten- bzw. Rauhfaserset
DE19744531A1 (de) 1997-10-09 1999-05-27 Klaus Dr Rer Nat Bosslet Bindemoleküle gegen Rezeptor-Ligand-Komplexe
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
DE10016877A1 (de) * 2000-04-05 2001-10-18 Scintec Diagnostics Gmbh Zug (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
ATE376000T1 (de) 2007-11-15
DE10016877A1 (de) 2001-10-18
EP1276770B1 (de) 2007-10-17
US20030171548A1 (en) 2003-09-11
CY1107136T1 (el) 2012-10-24
WO2001077179A1 (de) 2001-10-18
DK1276770T3 (da) 2008-02-18
EP1276770A1 (de) 2003-01-22
JP2003530126A (ja) 2003-10-14
US7264805B2 (en) 2007-09-04
US9005574B2 (en) 2015-04-14
US20080075659A1 (en) 2008-03-27
US20110008249A1 (en) 2011-01-13
PT1276770E (pt) 2008-01-24
DE50113151D1 (de) 2007-11-29
ES2295160T3 (es) 2008-04-16
US7820410B2 (en) 2010-10-26

Similar Documents

Publication Publication Date Title
JP2807213B2 (ja) フィブリンの検出方法
TWI294969B (enExample)
Purified from Antisera against Murphy Rat Lymphosarcoma
US5273738A (en) Radiation delivery to lymphoid and marrow tissues
JP2020022470A (ja) ヒト化抗カリクレイン−２抗体
Morell et al. In vivo Behaviour of Gamma Globulin Preparations 1
EP0163041B1 (en) Diagnostic agent for heart disease and use thereof
JPH0372894A (ja) 悪性腫瘍細胞の検出
US9005574B2 (en) Proteins with high immunoreactivity and method for their production
CN116212058B (zh) 一种靶向细胞凋亡的免疫pet分子影像探针
JP3291525B2 (ja) ヒトプラスミン−α▲下２▼−プラスミンインヒビター複合体の免疫学的測定方法
EP1482981B1 (en) Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
JPH02195876A (ja) ヒト―ヒトハイブリドーマの製造方法並びに該ハイブリドーマからモノクローナル及びポリクローナル抗体を製造する方法
JP2021511068A (ja) Ｃｅｎｔｒｉｎ−１に対する抗体、作製方法、及びその使用
US20230293738A1 (en) B7H3 Antibodies with Chelators
US6743411B2 (en) Extracorporal system for treating disease with radionucleotides
CN119874942B (zh) 一种放射性蛋白偶联药物及其应用
CN114848853B (zh) 一种靶向cd19抗体的多肽分子探针及其应用
Yuan et al. The invivo and in vitro immunogenicity and antigenic specificity of lymphoid antigen fragment-oligoribonucleopeptide conjugates
JP3036545B2 (ja) モノクローナル抗体とこれを産生するハイブリドーマ細胞株、およびこれを用いる免疫学的測定法
JPS62500585A (ja) モノクロ−ナル抗体およびその用途
CN118930652A (zh) 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用
CN118063610A (zh) 靶向tim3的抗体及其核素标记物与应用
Yadav Immunolocalization in SCID mice bearing human tumor using iodine-124 radiolabeled monoclonal antibody JAA-F11
JPH0413636A (ja) 乳癌診断薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101015

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110315

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111007

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111104

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111202

R150 Certificate of patent or registration of utility model

Ref document number: 4880854

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141209

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees